August 4, 2026

How a pharma megamerger could squelch R&D

(Axios) – Big drug companies have been buying scrappy biotechs to expand their pipelines, but the potential megamerger between AstraZeneca and Bristol Myers Squibb could flip that script. Why it matters: Combining two drug giants with overlapping portfolios could put … Read More

Posted by

Posted in News, Pharma